Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMSW) Other Non-Current Liabilities (2022 - 2024)

Historic Other Non-Current Liabilities for NewAmsterdam Pharma (NAMSW) over the last 3 years, with Q3 2024 value amounting to $18.8 million.

  • NewAmsterdam Pharma's Other Non-Current Liabilities changed N/A to $18.8 million in Q3 2024 from the same period last year, while for Sep 2024 it was $18.8 million, marking a year-over-year change of. This contributed to the annual value of $7.8 million for FY2023, which is 353.63% up from last year.
  • According to the latest figures from Q3 2024, NewAmsterdam Pharma's Other Non-Current Liabilities is $18.8 million.
  • NewAmsterdam Pharma's 5-year Other Non-Current Liabilities high stood at $18.8 million for Q3 2024, and its period low was $7.2 million during Q4 2022.
  • For the 3-year period, NewAmsterdam Pharma's Other Non-Current Liabilities averaged around $12.0 million, with its median value being $10.8 million (2023).
  • Per our database at Business Quant, NewAmsterdam Pharma's Other Non-Current Liabilities skyrocketed by 822.97% in 2023 and then skyrocketed by 6285.2% in 2024.
  • Over the past 3 years, NewAmsterdam Pharma's Other Non-Current Liabilities (Quarter) stood at $7.2 million in 2022, then rose by 8.23% to $7.8 million in 2023, then soared by 141.5% to $18.8 million in 2024.
  • Its Other Non-Current Liabilities stands at $18.8 million for Q3 2024, versus $13.4 million for Q2 2024 and $16.5 million for Q1 2024.